These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28941200)

  • 1. Decreased Neuro-Axonal Proteins in CSF at First Attack of Suspected Multiple Sclerosis.
    Stoop MP; Runia TF; Stingl C; van der Vuurst de Vries RM; Luider TM; Hintzen RQ
    Proteomics Clin Appl; 2017 Dec; 11(11-12):. PubMed ID: 28941200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate biomarkers in converting and non-converting clinically isolated syndrome by proteomics analysis of cerebrospinal fluid.
    Timirci-Kahraman O; Karaaslan Z; Tuzun E; Kurtuncu M; Baykal AT; Gunduz T; Tuzuner MB; Akgun E; Gurel B; Eraksoy M; Kucukali CI
    Acta Neurol Belg; 2019 Mar; 119(1):101-111. PubMed ID: 29873030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM.
    Kroksveen AC; Aasebø E; Vethe H; Van Pesch V; Franciotta D; Teunissen CE; Ulvik RJ; Vedeler C; Myhr KM; Barsnes H; Berven FS
    J Proteomics; 2013 Jan; 78():312-25. PubMed ID: 23059536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of natalizumab treatment on the cerebrospinal fluid proteome of multiple sclerosis patients.
    Stoop MP; Singh V; Stingl C; Martin R; Khademi M; Olsson T; Hintzen RQ; Luider TM
    J Proteome Res; 2013 Mar; 12(3):1101-7. PubMed ID: 23339689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.
    Hinsinger G; Galéotti N; Nabholz N; Urbach S; Rigau V; Demattei C; Lehmann S; Camu W; Labauge P; Castelnovo G; Brassat D; Loussouarn D; Salou M; Laplaud D; Casez O; Bockaert J; Marin P; Thouvenot E
    Mult Scler; 2015 Sep; 21(10):1251-61. PubMed ID: 25698171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.
    Comabella M; Fernández M; Martin R; Rivera-Vallvé S; Borrás E; Chiva C; Julià E; Rovira A; Cantó E; Alvarez-Cermeño JC; Villar LM; Tintoré M; Montalban X
    Brain; 2010 Apr; 133(Pt 4):1082-93. PubMed ID: 20237129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.
    Bastos P; Ferreira R; Manadas B; Moreira PI; Vitorino R
    Crit Rev Clin Lab Sci; 2017 May; 54(3):185-204. PubMed ID: 28393582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.
    Cantó E; Tintoré M; Villar LM; Borrás E; Alvarez-Cermeño JC; Chiva C; Sabidó E; Rovira A; Montalban X; Comabella M
    J Neuroinflammation; 2014 Nov; 11():181. PubMed ID: 25406498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
    Antonelou RCh; Emmanouilidou E; Gasparinatos G; Velona T; Voumvourakis KI; Stefanis L
    J Neurochem; 2015 Aug; 134(4):748-55. PubMed ID: 25962981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis.
    Jankovska E; Lipcseyova D; Svrdlikova M; Pavelcova M; Kubala Havrdova E; Holada K; Petrak J
    Int J Neurosci; 2022 Jul; 132(7):724-734. PubMed ID: 33059501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls.
    Kroksveen AC; Guldbrandsen A; Vedeler C; Myhr KM; Opsahl JA; Berven FS
    Acta Neurol Scand Suppl; 2012; (195):90-6. PubMed ID: 23278663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression.
    Nemecek A; Zimmermann H; Rübenthaler J; Fleischer V; Paterka M; Luessi F; Müller-Forell W; Zipp F; Siffrin V
    Mult Scler; 2016 Apr; 22(4):483-93. PubMed ID: 26163073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis.
    Opsahl JA; Vaudel M; Guldbrandsen A; Aasebø E; Van Pesch V; Franciotta D; Myhr KM; Barsnes H; Berle M; Torkildsen Ø; Kroksveen AC; Berven FS
    Proteomics; 2016 Apr; 16(7):1154-65. PubMed ID: 26841090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-based profiling of cerebrospinal fluid within multiple sclerosis.
    Häggmark A; Byström S; Ayoglu B; Qundos U; Uhlén M; Khademi M; Olsson T; Schwenk JM; Nilsson P
    Proteomics; 2013 Aug; 13(15):2256-67. PubMed ID: 23696371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 14-3-3 protein in multiple sclerosis: a marker of disease severity.
    Colucci M; Roccatagliata L; Capello E; Narciso E; Latronico N; Tabaton M; Mancardi GL
    Mult Scler; 2004 Oct; 10(5):477-81. PubMed ID: 15471360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis.
    Salazar IL; Lourenço AST; Manadas B; Baldeiras I; Ferreira C; Teixeira AC; Mendes VM; Novo AM; Machado R; Batista S; Macário MDC; Grãos M; Sousa L; Saraiva MJ; Pais AACC; Duarte CB
    J Neuroinflammation; 2022 Feb; 19(1):44. PubMed ID: 35135578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.